Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma

Journal of Surgical Oncology

Volumn 92, Issue 3, 2005, Pages 230-238

  Mooney, M M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Cancer Therapy and Evaluation Program   (United States)

Author keywords

Adjuvant; Chemoradiation; Chemotherapy; Esophageal cancer; Neoadjuvant therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUOROURACIL; VINBLASTINE; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; ESOPHAGEAL ADENOCARCINOMA; HUMAN; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 28844494120     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20364     Document Type: Review

References (35)

1. Parkin DM: International variation. Oncogene 2004;23:6329-6340.
2. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Blot WJ, Devesa SS, Kneller RW, et al.: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289.
4. Crew KD, Neugut AI: Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004;31:450-464.
5. Jemal A, Clegg LX, Ward E, et al.: Annual report to the nation of the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
6. Brenner B, Ilson D, Minsky BD: Treatment of localized esophageal cancer. Semin Oncol 2004;31:554-565.
7. Kelsen D: Preoperative chemoradiotherapy for esophageal cancer. J Clin Oncol 2001;19:283-285.
8. Lordick F, Stein HJ, Peschel C, et al.: Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004;91:540-551.
9. Burak WE: Is neoadjuvant therapy the answer to adenocarcinoma of the esophagus? Am J Surg 2003;186:296-300.
10. Kelsen D, Ginsberg R, Pajak TF, et al.: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984.
11. Oesophageal Medical Research Council Oesophageal Cancer Working Party: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomized controlled trial. Lancet 2002;359:1727-1733.
12. Kelsen D, Pajak T, Ginsberg R: Treatment of esophageal cancer. N Engl J Med 1999;340:1686-1687 (letter).
13. Malthaner R, Fenlon D: Preoperative chemotherapy for respectable thoracic esophageal cancer. The Cochrane Database of Systemic Reviews 2003, Issue 4. Art. No.: CD00L556.
14. Urshel JD, Vasan H, Blewett CJ: A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002;183:274-279.
15. Malthaner RA, Wong RKS, Rumble RB, et al.: Neoadjuvant or adjuvant therapy for respectable esophageal cancer: A systematic review and meta-analysis. BMC Med 2004;2:35.
16. Nygaard K, Hagen S, Hansen HS, et al: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multi-center study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-1109.
17. Le Prise E, Etienne PL, Meunier B, et al.: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779-1784.
18. Apinop C, Puttisak P, Preecha N: A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994;41:391-393.
19. Bosset JF, Gignoux M, Triboulet JP, et al.: Chemoradiotherapy followed by surgery compared to surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167.
20. Walsh TN, Noonan N, Hollywood D. et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467.
21. Urba SG, Orringer MB, Turrisi A, et al.: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313.
22. Burmeister BH, Smithers BM, Fitzgerald L, et al.: A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus. Proc Am Soc Clin Oncol 2002;518 (abstract).
23. Urshel JD, Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185:538-543.
24. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
25. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy in operable gastric and lower esophageal cancer. Final results of a randomised, controlled trial (the MAGIC trial ISRCTN 93793971). Proc Am Soc Clin Oncol 2005;23:4001 (abstract and oral/slide presentation).
26. Khushalani NI, Leichman CG, Proulx G, et al.: Oxaliplatin in combination with protracted infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002;20:2844-2850.
27. Brenner B, Ilson DH, Minsky BD, et al.: Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004;22:45-52.
28. Daluvoy S, Rosato EL, Cowan S, et al.: Neoadjuvant chemoradiotherapy with 5-fluorouracil, (5-FU), carboplatinum (C) and paclitaxel (T) dramatically improves survival in patients with clinical stage 2 and 3 adenocarcinoma of the distal esophagus and GE junction compared to surgery alone. Program and Abstracts Am Soc Clin Oncol 2005 GI Cancers Symposium; January 27-29, 2005; Hollywood, FL. Abstract 35.
29. Ajani JA, Walsh G, Komaki R, et al.: Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus and gastroesophageal junction. Cancer 2004;100:2347-2354.
30. Shah MA, Ilson D, Saltz L, et al.: A multi-center phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (Bev) in patients with unresectable or metastatic gastric or gastroesophageal (GEJ) adenocarcinoma. Program and Abstracts Am Soc Clin Oncol 2005 GI Cancers Symposium; January 27-29, 2005; Hollywood, FL. Abstract 26.
31. Dragovich T, McCoy S, Urba SG, et al.: SWOG 0127: Phase II trial of erlotinib in GEJ and gastric adenocarcinomas. Program and Abstracts Am Soc Clin Oncol 2005 GI Cancers Symposium; January 27-29, 2005; Hollywood, FL. Abstract 49.
32. Ilson DH: Oesophageal cancer: New developments in systemic therapy. Cancer Treat Rev 2003;29:525-532.
33. Weber WA, Ott K, Becker K, et al.: Prediction of response to preoperative chemotherapy in adenocarcinoma of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3066.
34. Downey RJ, Ilson D, Koong H, et al.: 18FDG PET measures the pathologic response of esophageal cancer to induction therapy. Proc Am Soc Clin Oncol 2001;20:503 (abstract).
35. Flamen P, Van Cutsem E, Lerut T, et al.: The utility of positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) to predict the pathologic response and survival of esophageal cancer after preoperative chemoradiation therapy (CRT). Proc Am Soc Clin Oncol 2001;20:504 (abstract).